Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07829874 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Cryoablation Combined With QL1706 (Iparomlimab/Tuvonralimab) Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer.

Name: Cryoablation Combined With QL1706 (Iparomlimab/Tuvonralimab) Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer. — clinical trial record (NCT07829874)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: CASTLE-ZS-04

StatusNot Yet Recruiting

PhasePhase 2

SponsorFudan University

Started2026-09-20

View on ClinicalTrials.gov ↗

Fudan University

624 trials monitored

See 9 trials at risk

Cholangiocarcinoma

611 trials monitored

See 25 trials at risk

This study will evaluate the efficacy and safety of cryoablation combined with QL1706 (iparomlimab/tuvonralimab) plus lenvatinib in patients with advanced biliary tract cancer (BTC) who have progressed after first-line treatment.

Trial Details

NCT Number	NCT07829874
Lead Sponsor	Fudan University
Conditions	Biliary Tract Cancer (BTC)
Enrollment	180 participants
Start Date	2026-09-20
Primary Completion	2028-09-20 (estimated)
Study Completion	2029-09-20 (estimated)
Updated on ClinicalTrials.gov	2026-09-21